Lucid Genomics
AI-powered solutions that translate 100% of genetic information into valuable insights for accelerated drug discovery.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
* | €1.3m | Seed | |
| Total Funding | 000k | ||
Related Content
Lucid Genomics is a German health-tech company that has developed an AI-powered platform for whole genome analysis. The company's technology is capable of analyzing both coding and non-coding DNA, including the so-called "dark genome," which was previously inaccessible. This allows for a more comprehensive and accurate identification of genetic variations, which can be used for research, drug development, and diagnostics.
The company's platform is based on machine learning algorithms that have been trained on a large dataset of genomic data. This allows the platform to identify even subtle genetic variations that may be missed by other methods. The company's business model is based on providing its platform as a service to pharmaceutical companies, research institutions, and diagnostic laboratories.
Lucid Genomics was founded as a spin-off of the Max Planck Institute for Molecular Genetics and Charité - Universitätsmedizin Berlin. The company has recently secured €1.3 million in pre-seed funding to further develop its AI models and expand its commercial operations.
Keywords: genomics, AI, machine learning, DNA sequencing, dark genome, genetic variations, diagnostics, drug development, personalized medicine, health-tech